Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Crenigacestat in Healthy Subjects
NCT02906618Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crenigacestat in solid tumor, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration and Area Under the Concentration Versus Time Curve From Zero to Infinity. Started Oct 2016; status: completed.
02
Drugs
crenigacestat
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02906618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906618.